Vaccination of pregnant sows against transmissible gastroenteritis with two attenuated virus strains and different inoculation routes.
Two attenuated transmissible gastro-enteritis (T.G.E.) virus strains were used for vaccination experiments in sows. Four different experiments were carried out (see Table 1). In each experiment, 9 sows were vaccinated during pregnancy and 3 sows served as controls. They were kept together in one farrowing house. The sows were due to farrow at about the same time. The sows and their litters were challenged shortly after farrowing by exposing 3 piglets of 2 controls litters to virulent TGE virus. The following vaccination schedules were used (see Table 1): twice intramuscularly with TGE-vac (a commercially available TGE-vaccine), one oral administration followed by an intramuscular vaccination with an attenuated TGE Purdue (Pu) strain, twice orally with Pu strain in enteric coated capsules, and one direct intra intestinal administration followed by 2 intramuscular vaccinations or 3 intramuscular vaccinations with the Pu strain. All sows, except most of those treated with enteric coated capsules, seroconverted demonstrably (Table 2). The geometric mean seroneutralization (SN) titer log 2 varied from 4.1 to 7.5 after the first vaccination and from 7.6 to 10 after the second vaccination. None of the vaccination schedules resulted in an effective lactogenic immunity. The morbidity in the piglets was 100% within 3 to 5 days after challenge. The mortality rate varied from 44 to 80% in litters from vaccinated sows and from 71 to 100% in litters from control sows (see Table 3). Clinical signs were observed in 33.3% of the control sows and in 36% of the vaccinated sows. No correlation was found between the titer of SN antibodies in the sera of the piglets and their survival rate (Table 4). A rapid decrease in antibody concentration was observed, during the first week of lactation in milk samples collected from 4 orally and intramuscularly vaccinated sows (Table 5).
D000818:Animals; D000914:Antibodies, Viral / Q000302:isolation & purification; D003332:Coronaviridae / Q000276:immunology*; D005260:Female; D005761:Gastroenteritis, Transmissible, of Swine / Q000517:prevention & control*; D008892:Milk / Q000276:immunology; D011247:Pregnancy; D013552:Swine; D014613:Vaccines, Attenuated; D014765:Viral Vaccines / Q000008:administration & dosage / Q000627:therapeutic use*
D000914:Antibodies, Viral; D014613:Vaccines, Attenuated; D014765:Viral Vaccines